Humacyte, Inc. HUMA
We take great care to ensure that the data presented and summarized in this overview for Humacyte, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HUMA
View all-
Black Rock Inc. New York, NY4.79MShares$34.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.02MShares$28.7 Million0.0% of portfolio
-
Aigh Capital Management LLC Baltimore, MD2.16MShares$15.4 Million2.7% of portfolio
-
Sio Capital Management, LLC New York, NY2MShares$14.3 Million2.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.35MShares$9.66 Million0.0% of portfolio
-
State Street Corp Boston, MA1.21MShares$8.67 Million0.0% of portfolio
-
Monashee Investment Management LLC Boston, MA1MShares$7.15 Million0.43% of portfolio
-
Prescott General Partners LLC Boca Raton, FL568KShares$4.06 Million0.1% of portfolio
-
Northern Trust Corp Chicago, IL550KShares$3.93 Million0.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA474KShares$3.39 Million0.0% of portfolio
Latest Institutional Activity in HUMA
Top Purchases
Top Sells
About HUMA
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Insider Transactions at HUMA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 20
2024
|
Charles Bruce Green Director |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+33.33%
|
$2,400
$4.09 P/Share
|
|
May 20
2024
|
Max N. Wallace Director |
BUY
Open market or private purchase
|
Indirect |
8,005
+50.0%
|
$48,030
$6.25 P/Share
|
|
May 17
2024
|
Charles Bruce Green Director |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+50.0%
|
$2,400
$4.09 P/Share
|
|
May 15
2024
|
Gordon M Binder Director |
BUY
Open market or private purchase
|
Direct |
50,000
+23.81%
|
$300,000
$6.78 P/Share
|
|
May 15
2024
|
Gordon M Binder Director |
BUY
Open market or private purchase
|
Indirect |
50,000
+50.0%
|
$300,000
$6.57 P/Share
|
|
Nov 21
2023
|
Max N. Wallace Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,564
+10.4%
|
$6,564
$1.19 P/Share
|
|
Oct 10
2023
|
Brady W Dougan Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
114,420
+7.63%
|
$114,420
$1.19 P/Share
|
|
Oct 10
2023
|
Laura E Niklason President, CEO and Director |
BUY
Exercise of conversion of derivative security
|
Direct |
114,420
+7.63%
|
$114,420
$1.19 P/Share
|
|
Sep 14
2023
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
2,000,000
-24.42%
|
$4,000,000
$2.78 P/Share
|
|
Sep 14
2023
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
2,000,000
-24.42%
|
$4,000,000
$2.78 P/Share
|
|
Aug 21
2023
|
Ayabudge LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
602,443
-6.85%
|
$1,807,329
$3.39 P/Share
|
|
Aug 21
2023
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
602,443
-6.85%
|
$1,807,329
$3.39 P/Share
|
|
Aug 21
2023
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
602,443
-6.85%
|
$1,807,329
$3.39 P/Share
|
|
Aug 18
2023
|
Ayabudge LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
626,979
-6.66%
|
$1,880,937
$3.57 P/Share
|
|
Aug 18
2023
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
626,979
-6.66%
|
$1,880,937
$3.57 P/Share
|
|
Aug 18
2023
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
626,979
-6.66%
|
$1,880,937
$3.57 P/Share
|
|
Aug 17
2023
|
Ayabudge LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
570,174
-5.71%
|
$1,710,522
$3.68 P/Share
|
|
Aug 17
2023
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
570,174
-5.71%
|
$1,710,522
$3.68 P/Share
|
|
Aug 17
2023
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
570,174
-5.71%
|
$1,710,522
$3.68 P/Share
|
|
Jun 15
2023
|
Ayabudge LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
500,000
-4.77%
|
$1,500,000
$3.12 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 108K shares |
|---|---|
| Exercise of conversion of derivative security | 237K shares |
| Open market or private sale | 25.5M shares |
|---|